After completion of study therapy, patients are followed up for 4 weeks.

Inclusion Criteria:

- Histologically or cytologically confirmed prostate cancer

- Measurable or non-measurable disease

- Measurable defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm by conventional techniques or as ≥ 10 mm by spiral CT scan

- Lymph nodes considered measurable if ≥ 20 mm

- Non-measurable are all other lesions, including small lesions (longest diameter < 20 mm by conventional techniques or < 10 mm by spiral CT scan) and the following:

- Bone lesions

- Leptomeningeal disease

- Ascites

- Lymphangitis cutis/pulmonis

- Inflammatory breast disease

- Abdominal masses not followed by CT or MRI

- Cystic lesions

- Patients with elevation of PSA alone without measurable or nonmeasurable disease are not eligible

- Must have received prior hormonal therapy with medical (LHRH agonist) or surgical (orchiectomy) castration

- Castrate level of testosterone (< 50 ng/dL) required (baseline measurement of test not required for patients who have had surgical castration)

- Clinical and/or radiographic evidence of progression on or after docetaxel therapy

- No active pleural or pericardial effusion of any grade

- No meningeal metastases or untreated known brain metastases

- Patients with treated brain metastasis with radiologic and clinical evidence of stability, with no evidence of cavitation or hemorrhage in the brain lesions allowed provided that they are asymptomatic and do not require corticosteroids

- More than 5 years since any malignancy except in situ cancer, non-metastatic basal or squamous cell skin cancer, or other cancer for which the patient has been curatively treated by definitive primary therapy alone and has been continuously disease-free

- Fertile patients must use effective contraception

- No condition that potentially impairs ability to swallow or absorb, including any of the following:

- Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation

- Active peptic ulcer disease

- Short gut syndrome

- Malabsorption syndrome of any type

- Total or partial bowel obstruction

- Inability to tolerate oral medications

- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or dasatinib

- Concurrent medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of cediranib and dasatinib will be determined following review of their case by the principal investigator or co-investigator

- At least 14 days before and after study and no concurrent CYP3A4-active agents or substances (including strong inhibitors or inducers)

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.